13F Holdings
中文EN

ADCT ADC Therapeutics SA

Pharmaceutical Preparations · NYSE · SEC CIK 1771910 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.8%
TTM net income YoY51.3%
TTM EPS YoY67.4%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-97.7%
Net margin-95.7%
FCF margin-118.5%
EBITDA margin—

Returns

ROE—
ROA-29.8%
ROIC (approx.)—
Asset turnover0.31x

Leverage & solvency

Liabilities / assets197.4%
Debt / equity—
Current ratio3.05x
Interest coverage-1.58x

Cash quality & payout

Operating cash flow / net income1.24x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$81.36M$70.84M$69.56M$209.91M$33.92M
Cost of revenue$5.80M$5.95M$2.53M$3.30M$1.39M
Gross profit$75.56M$64.89M$67.03M$206.61M$32.52M
R&D expense$104.00M$109.63M$127.13M$186.46M$158.00M
SG&A expense$36.56M$41.89M$48.42M$74.44M$71.46M
Operating income-$121.50M-$130.65M-$165.99M-$123.34M-$261.72M
Interest expense$51.63M$50.21M$46.33M$36.73M$18.34M
Pretax income-$141.61M-$156.14M-$195.42M-$146.82M-$251.50M
Income tax$1.01M$166,000$39.11M$227,000-$21.48M
Net income-$142.62M-$157.85M-$240.05M-$157.13M-$230.03M
EBITDA-$120.79M-$129.32M-$164.80M-$122.28M—
EPS (basic)-1.12-1.62-2.94-2.01—
EPS (diluted)-1.12-1.62-2.94-2.01—
Weighted avg. shares (diluted)127.07M97.16M81.71M78.15M—
Balance sheet
Cash & equivalents$261.34M$250.87M$278.60M$326.44M$466.54M
Receivables———$72.97M$30.22M
Inventory$4.18M$2.25M$16.18M$12.07M$11.12M
Current assets$306.33M$291.25M$336.29M$434.98M$525.18M
PP&E, net$0$5.08M$5.62M$3.35M$4.07M
Intangibles———$14.36M$13.58M
Total assets$323.15M$321.98M$354.78M$490.86M$617.97M
Current liabilities$70.16M$80.47M$67.67M$81.94M$73.94M
Short-term debt$3.00M$0—$12.47M$6.58M
Long-term debt————$87.15M
Total debt————$93.73M
Total liabilities$508.98M$524.62M$503.03M$411.41M$451.88M
Shareholders' equity-$185.83M-$202.64M-$148.25M$79.45M$154.03M
Net debt————-$372.82M
Shares outstanding125.75M98.86M82.29M80.64M—
Cash flow statement
Operating cash flow-$141.17M-$123.83M-$118.69M-$138.31M-$233.38M
Capital expenditure$264,000$867,000$3.22M$687,000$3.43M
Free cash flow-$141.44M-$124.70M-$121.90M-$139.00M-$236.81M
Investing cash flow$395,000-$867,000-$3.22M-$687,000-$6.67M
Financing cash flow$150.94M$97.05M$73.88M-$897,000$267.39M
Depreciation & amortization$705,000$1.33M$1.19M$1.06M—
Stock-based compensation$6.91M$6.57M$13.49M$49.32M$60.48M
Share buybacks————$0

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.